

Colgate-Palmolive India | HOLD

Toothpaste market share looking steadier now

Colgate's 4QFY18 volume growth was a tad below our forecast at 4% - on a soft comparator, though (volume had declined 3% in 4Q LY due to the continued impact of demonetisation). Overall revenue, though, was significantly lower (470bps) vs expectations due to a rather sharp deceleration in net realisation growth to merely 1% in 4Q vs 4-6% in past 6M - possibly a function of Colgate's pre-GST price-hike having now anniversarised. On the positive side, toothpaste market share appears to have now stabilised for past 9M at c.53% without any incremental loss therein. On the flip side, management is pointing to a volume growth trajectory of just 4-5% level for the company going forward, which is a tad lower vs the current industry growth rate of 5.5-6%. The other disappointment is that Colgate's naturals portfolio appears to be growing at half the rate (c.10%) of industry (c.20-21% - was 30%+ earlier). Stock seems quite reasonably valued on relative basis at c.43x NTM EPS which is a c.15% discount to sector ex-ITC average of 50-51x, but lacks near-term trigger, in our view. Interestingly, Colgate's trailing (FY18) EV-EBITDA of 29x is lower vs HUL's 2-year forward (FY20) EV-EBITDA of 32-33x.

- **4% volume growth off a soft base:** Colgate's 4QFY18 sales, EBITDA and adjusted net profit grew 5.1%, 26.6% and 25.2% to INR10.9bn (net of all taxes), INR3.1bn and INR1.8bn respectively. Revenue was 4-5% below our forecasts (mostly due to lower realisation) while earnings, on the other hand, were 3-4% ahead on the back of much sharper than anticipated GPM expansion (3ppt vs JMFe of 1.3ppt) and lower SG&A (flattish YoY vs expected increase of 7%). Overall volumes grew 4% which is only a tad below our expectation of 5% but have lagged the industry growth rate of 5.7% - a key result disappointment. Realisation growth turned out much lower vs our forecast - grew merely 1% YoY vs past 6M's 4-6% as the company has not effected any realisation hike post GST (retail prices were, in fact, lowered to pass on GST benefits to consumers) and the pre-GST hike has anniversarised by 4Q. Management, however, opined that prices are likely to go up sooner or later since input-costs have now turned inflationary. Colgate's 'Swarna Vedshakti' now constitutes c.4% of its turnover and the brand is now planned to be scaled up nationally (currently present only in the South).
- **Margin gains were much stronger than anticipated:** Pace of GPM expansion accelerated to 300bps vs 150bps in 3Q and 50-100bps seen in earlier 6M - some base-effect is also at play, though - GPM was quite similar QoQ. EBITDA margin expansion was even sharper at 480bps which was further helped by cost efficiencies as SG&A was largely flattish during the quarter - tax-credits now available under GST likely helped to some extent. The flattish A&P during the quarter was, as per management, a function of high base as spends had grown 24% in 4Q LY. Adjusted net profit growth of 25% was a tad below EBITDA growth due to decline in other income and higher tax rate.
- **Toothpaste share seems to have stabilized over past 9M:** Colgate's toothpaste volume market share for FY18 stood at 53.4% - while this is 170bps lower vs FY17's print of 55.1%, our workings indicate that Colgate's toothpaste share has now broadly stabilised at c.53% level over the past 9M. The toothbrush business, on the other hand, appears to have gained 220bps of share in the past 3M, as per our workings, though share for FY18 (44.8%) was 260bps lower vs FY17's.



Richard Liu

richard.liu@jmfll.com | Tel: (91 22) 66303064

Vicky Punjabi

vicky.punjabi@jmfll.com | Tel: (91 22) 66303065

Recommendation and Price Target

Current Reco.	HOLD
Previous Reco.	HOLD
Current Price Target (12M)	1,240
Upside/(Downside)	2.6%
Previous Price Target	1,225
Change	1.2%

Key Data - CLGT IN

Current Market Price	INR1,208
Market cap (bn)	INR328.7/US\$4.8
Free Float	43%
Shares in issue (mn)	272.0
Diluted share (mn)	272.0
3-mon avg daily val (mn)	INR403.1/US\$5.9
52-week range	1,285/975
Sensex/Nifty	34,616/10,517
INR/US\$	68.1

Price Performance

%	1M	6M	12M
Absolute	9.6	15.7	18.9
Relative*	9.0	11.9	4.6

* To the BSE Sensex

Financial Summary

Y/E March	FY16A*	FY17A	FY18E	FY19E	FY20E
Sales	43,190	44,898	42,999	46,362	51,482
Sales growth (%)	9.2	4.0	-4.2	7.8	11.0
EBITDA	9,385	9,449	11,124	12,692	14,515
EBITDA (%)	21.7	21.0	25.9	27.4	28.2
Adjusted net profit	5,708	5,613	6,464	7,372	8,418
EPS (INR)	21.0	20.6	23.8	27.1	30.9
EPS growth (%)	2.1	-1.7	15.2	14.0	14.2
ROIC (%)	97.0	66.3	65.9	66.6	74.6
ROE (%)	63.4	48.7	46.2	51.4	58.3
PE (x)	57.6	58.5	50.8	44.6	39.0
Price/Book Value (x)	31.9	25.8	21.6	24.4	21.3
EV/EBITDA (x)	34.7	34.4	29.1	25.7	22.3
Dividend Yield (%)	0.8	0.8	2.0	1.5	1.7

Source: Company data, JM Financial. Note: Valuations as of 21/May/2018

JM Financial Institutional Securities Limited

JM Financial Research is also available on:
Bloomberg - JMFR <GO>,
Thomson Publisher & Reuters
S&P Capital IQ and FactSet

Please see Appendix I at the end of this report for Important Disclosures and Disclaimers and Research Analyst Certification.

Exhibit 1. 4Q & FY18 result snapshot

	4QFY18	4QFY17	YoY chg	4QFY18E	% var	(INR mn)		
						FY18	FY17	YoY chg
Net Sales	10,851	10,326	5.1%	11,384	-4.7%	41,594	39,515	5.3%
Other Operating Income	66	49	33.6%	62	6.9%	285	304	-6.0%
Total Revenue	10,917	10,375	5.2%	11,446	-4.6%	41,880	39,818	5.2%
Gross Profit	7,101	6,449	10.1%	7,252	-2.1%	26,694	24,751	7.8%
Gross Profit Margin %	65.4%	62.5%	299 bps	63.7%	174 bps	64.2%	62.6%	154 bps
Staff Cost	758	763	-0.6%	831	-8.8%	3,059	2,885	6.0%
A&P	1,436	1,443	-0.5%	1,531	-6.2%	5,268	5,117	3.0%
Other Expenses	1,898	1,862	1.9%	1,992	-4.7%	7,528	7,617	-1.2%
EBITDA	3,075	2,430	26.6%	2,959	3.9%	11,124	9,436	17.9%
EBITDA margin %	28.3%	23.5%	481 bps	26.0%	235 bps	26.7%	23.9%	286 bps
Depreciation	405	341	18.6%	398	1.6%	1,565	1,332	17.5%
EBIT	2,670	2,089	27.8%	2,561	4.3%	9,559	8,103	18.0%
EBIT margin %	24.6%	20.2%	438 bps	22.5%	212 bps	23.0%	20.5%	247 bps
Net Financial Other Income	85	93	-9.0%	91	-6.9%	388	411	-5.6%
PBT	2,755	2,182	26.3%	2,652	3.9%	9,947	8,514	16.8%
PBT after exceptional	2,639	2,182	20.9%	2,652	-0.5%	9,830	8,514	15.5%
Tax	751	756	-0.7%	915	-18%	3,097	2,740	13.0%
Net Profit	1,888	1,426	32.4%	1,737	8.7%	6,734	5,774	16.6%
Adjusted Net Profit	1,785	1,426	25.2%	1,737	2.8%	6,464	5,613	15.2%


Source: Company, JM Financial

Exhibit 2. Costs breakdown

% of sales	4QFY18	4QFY17	4QFY18E	FY18	FY17
Cost of Goods Sold	34.6%	37.5%	36.3%	35.8%	37.4%
Staff Cost	7.0%	7.4%	7.3%	7.4%	7.3%
Advertisement	13.2%	14.0%	13.5%	12.7%	13.0%
Other Expenses	17.5%	18.0%	17.5%	18.1%	19.3%


Source: Company, JM Financial

Exhibit 3. Operating margin movement – 4QFY18




Source: Company, JM Financial

Exhibit 4. Quarterly sales growth trend




Source: Company, JM Financial

Exhibit 5. Toothpaste volume growth trend




Source: Company, JM Financial

Exhibit 6. A&P trend




Source: Company, JM Financial

Exhibit 7. Adjusted net profit growth trend




Source: Company, JM Financial

Exhibit 8. Colgate - toothpaste market share trend



Source: Company, JM Financial

Exhibit 9. Toothpaste market share showing some stability




Source: Company, JM Financial

Exhibit 10. Toothpaste market growth trends




Source: A C Nielsen, Company, JM Financial

Exhibit 11. Toothpaste volume market share trends




Source: A C Nielsen, Company, JM Financial

Exhibit 12. Toothbrush market growth trends



Source: A C Nielsen, Company, JM Financial

Exhibit 13. Toothbrush volume market share trends




Source: A C Nielsen, Company, JM Financial

Exhibit 14. Summary of estimate changes

(INR mn)

Colgate	FY18	FY19	FY20
Current			
Sales	42,999	46,362	51,482
EBITDA	11,124	12,692	14,515
Adjusted Net Profit	6,464	7,372	8,418
EPS	23.8	27.1	30.9
Earlier			
Sales	47,872	53,105	59,588
EBITDA	10,942	12,419	14,253
Adjusted Net Profit	6,491	7,427	8,633
EPS	23.9	27.3	31.7
Change - %			
Sales	-10.2%	-12.7%	-13.6%
EBITDA	1.7%	2.2%	1.8%
Adjusted Net Profit	-0.4%	-0.7%	-2.5%
EPS	-0.4%	-0.7%	-2.5%

Source: Company, JM Financial

Exhibit 15. Colgate one-year forward PE band

Source: Company, JM Financial

Financial Tables (Standalone)

Profit & Loss Statement (INRmn)					
Y/E March	FY16A*	FY17A	FY18E	FY19E	FY20E
Net sales (Net of excise)	43,190	44,898	42,999	46,362	51,482
Growth (%)	9.2%	4.0%	-4.2%	7.8%	11.0%
Other Operating Income	301	304	285	313	348
Total Revenue	43,491	45,202	43,284	46,675	51,830
Cost of Goods Sold/Op. Exp.	19,572	20,147	16,305	16,207	17,750
Personnel cost	2,624	2,885	3,059	3,431	3,799
Other expenses	11,910	12,721	12,796	14,345	15,765
EBITDA	9,385	9,449	11,124	12,692	14,515
EBITDA (%)	21.7%	21.0%	25.9%	27.4%	28.2%
EBITDA Growth (%)	14.1%	0.7%	17.7%	14.1%	14.4%
Depn & Amort	1,114	1,332	1,565	1,766	1,973
EBIT	8,271	8,116	9,559	10,926	12,543
Other Income	395	398	388	345	328
Finance Cost	0	0	0	0	0
PBT before Excep & Forex	8,666	8,514	9,947	11,271	12,870
Excep & forex Inc/Loss(-)	-313	0	-117	0	0
PBT	8,353	8,514	9,830	11,271	12,870
Taxes	2,541	2,740	3,097	3,899	4,452
Extraordinary Inc/Loss(-)	0	0	0	0	0
Assoc. Profit/Min. Int.(-)	0	0	0	0	0
Reported Net profit	5,812	5,774	6,734	7,372	8,418
Adjusted Net Profit	5,708	5,613	6,464	7,372	8,418
Net Margin (%)	13.2%	12.5%	15.0%	15.9%	16.4%
Diluted share capital (mn)	272.0	272.0	272.0	272.0	272.0
Diluted EPS (Rs)	21.0	20.6	23.8	27.1	30.9
Diluted EPS Growth	2.1%	-1.7%	15.2%	14.0%	14.2%
Total Dividend + Tax	3,274	3,289	7,894	5,898	6,734
Dividend Per Share (Rs)	10.0	10.0	24.0	18.0	20.6

Source: Company, JM Financial

Balance Sheet (INRmn)					
Y/E March	FY16A*	FY17A	FY18E	FY19E	FY20E
Shareholders' Fund	10,310	12,738	15,246	13,445	15,407
Share capital	272	272	272	272	272
Reserves & Surplus	10,038	12,466	14,974	13,173	15,135
Preference Share Capital	0	0	0	0	0
Minority Interest	0	0	0	0	0
Total Loans	0	0	0	0	0
Def. Tax Liab / Assets (-)	97	275	355	271	174
Total - Equity & Liab	10,407	13,013	15,601	13,715	15,581
Net Fixed Assets	10,865	12,747	13,045	13,279	13,306
Gross Fixed Assets	11,184	13,517	15,380	17,380	19,380
Intangible Assets	0	0	0	0	0
Less: Depn. & Amort.	1,103	2,435	4,001	5,767	7,739
Capital WIP	784	1,666	1,666	1,666	1,666
Investments	312	312	312	374	449
Current Assets	8,852	10,175	12,282	10,484	13,336
Inventories	2,915	2,926	2,267	2,921	3,244
Sundry Debtors	1,015	1,299	2,010	1,905	2,116
Cash & Bank Balances	2,887	2,943	4,562	1,983	4,053
Loans & Advances	1,021	1,770	2,256	2,368	2,487
Other Current Assets	1,013	1,238	1,188	1,306	1,437
Current Liab. & Prov.	9,622	10,221	10,037	10,421	11,510
Current Liabilities	7,918	8,669	8,769	8,753	9,611
Provisions & Others	1,703	1,552	1,268	1,668	1,898
Net Current Assets	-770	-46	2,245	63	1,826
Application of Funds	10,407	13,013	15,601	13,715	15,581

Source: Company, JM Financial

Cash Flow Statement (INRmn)					
Y/E March	FY16A*	FY17A	FY18E	FY19E	FY20E
Profit before Tax	8,353	8,514	9,830	11,271	12,870
Depn. & Amort.	1,114	1,332	1,565	1,766	1,973
Net Interest Exp. / Inc. (-)	-395	-398	-388	-345	-327
Inc (-) / Dec in WCap.	156	311	-410	-686	198
Others	183	135	80	-85	-97
Taxes Paid	-2,524	-3,014	-3,359	-3,610	-4,344
Operating Cash Flow	6,887	6,880	7,319	8,312	10,272
Capex	-2,713	-3,212	-1,863	-2,000	-2,000
Free Cash Flow	4,175	3,668	5,456	6,312	8,272
-Inc/dec in investments	70	0	0	-62	-75
Other current assets	277	-209	388	345	328
Investing Cash Flow	-2,366	-3,422	-1,475	-1,717	-1,747
Inc(dec) in capital	0	0	0	0	0
Dividend+Tax Thereon	-3,758	-3,270	-2,631	-9,173	-6,455
Inc/dec in loans	0	0	0	0	0
Other assets	-157	-135	-1,594	0	0
Financing Cash Flow	-3,914	-3,405	-4,226	-9,173	-6,455
Inc / Dec (-) in Cash	607	53	1,619	-2,579	2,070
Opening cash balance	2,280	2,890	2,943	4,562	1,983
Closing cash balance	2,887	2,943	4,562	1,983	4,053

Source: Company, JM Financial

*Note: Growth for FY16 shown in above impacted by Ind-AS transition. FY16 LTL Sales, EBITDA and adjusted EPS grew 4.5%, 13.3% and 1.3% respectively


Dupont Analysis					
Y/E March	FY16A*	FY17A	FY18E	FY19E	FY20E
Net Margin	13.2%	12.5%	15.0%	15.9%	16.4%
Asset Turnover (x)	4.8	3.8	3.0	3.2	3.5
Leverage Factor (x)	1.0	1.0	1.0	1.0	1.0
RoE	63.4%	48.7%	46.2%	51.4%	58.3%
Key Ratios					
Y/E March	FY16A*	FY17A	FY18E	FY19E	FY20E
BV/Share (INR)	37.9	46.8	56.1	49.4	56.6
ROIC (%)	97.0%	66.3%	65.9%	66.6%	74.6%
ROE (%)	63.4%	48.7%	46.2%	51.4%	58.3%
Net Debt-equity ratio (x)	-0.3	-0.3	-0.3	-0.2	-0.3
PER	57.6	58.5	50.8	44.6	39.0
PBV	31.9	25.8	21.6	24.4	21.3
EV/EBITDA	34.7	34.4	29.1	25.7	22.3
EV/Net Sales	7.5	7.2	7.5	7.0	6.3
Debtor days	9	11	17	15	15
Inventory days	25	24	19	23	23
Creditor days	85	89	100	94	94

Source: Company, JM Financial

History of Earnings Estimate and Target Price

Date	Recommendation	Target Price	% Chg.
31-Jul-15	Sell	1,880	
30-Oct-15	Sell	940	-50.0
9-Aug-16	Sell	960	2.1
28-Oct-16	Sell	945	-1.6
27-Jan-17	Hold	950	0.5
16-May-17	Hold	940	-1.1
3-Aug-17	Hold	1,135	20.7
16-Oct-17	Hold	1,170	3.1
5-Feb-18	Hold	1,170	0.0

Recommendation History



APPENDIX I

JM Financial Institutional Securities Limited

(formerly known as JM Financial Securities Limited)

Corporate Identity Number: U67100MH2017PLC296081

Member of BSE Ltd., National Stock Exchange of India Ltd. and Metropolitan Stock Exchange of India Ltd.

SEBI Registration Nos.: Stock Broker - INZ000163434, Research Analyst – INH000000610

Registered Office: 7th Floor, Energy, Appasaheb Marathe Marg, Prabhadevi, Mumbai 400 025, India.

Board: +9122 6630 3030 | Fax: +91 22 6630 3488 | Email: jmfinancial.research@jmfl.com | www.jmfl.comCompliance Officer: Mr. Sunny Shah | Tel: +91 22 6630 3383 | Email: sunny.shah@jmfl.com

Definition of ratings	
Rating	Meaning
Buy	Total expected returns of more than 15%. Total expected return includes dividend yields.
Hold	Price expected to move in the range of 10% downside to 15% upside from the current market price.
Sell	Price expected to move downwards by more than 10%

Research Analyst(s) Certification

The Research Analyst(s), with respect to each issuer and its securities covered by them in this research report, certify that:

All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and

No part of his or her or their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

Important Disclosures

This research report has been prepared by JM Financial Institutional Securities Limited (JM Financial Institutional Securities) to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its associates solely for the purpose of information of the select recipient of this report. This report and/or any part thereof, may not be duplicated in any form and/or reproduced or redistributed without the prior written consent of JM Financial Institutional Securities. This report has been prepared independent of the companies covered herein.

JM Financial Institutional Securities is registered with the Securities and Exchange Board of India (SEBI) as a Research Analyst and a Stock Broker having trading memberships of the BSE Ltd. (BSE), National Stock Exchange of India Ltd. (NSE) and Metropolitan Stock Exchange of India Ltd. (MSEI). No material disciplinary action has been taken by SEBI against JM Financial Institutional Securities in the past two financial years which may impact the investment decision making of the investor.

JM Financial Institutional Securities renders stock broking services primarily to institutional investors and provides the research services to its institutional clients/investors. JM Financial Institutional Securities and its associates are part of a multi-service, integrated investment banking, investment management, brokerage and financing group. JM Financial Institutional Securities and/or its associates might have provided or may provide services in respect of managing offerings of securities, corporate finance, investment banking, mergers & acquisitions, broking, financing or any other advisory services to the company(ies) covered herein. JM Financial Institutional Securities and/or its associates might have received during the past twelve months or may receive compensation from the company(ies) mentioned in this report for rendering any of the above services.

JM Financial Institutional Securities and/or its associates, their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) covered under this report or (c) act as an advisor or lender/borrower to, or may have any financial interest in, such company(ies) or (d) considering the nature of business/activities that JM Financial Institutional Securities is engaged in, it may have potential conflict of interest at the time of publication of this report on the subject company(ies).

Neither JM Financial Institutional Securities nor its associates or the Research Analyst(s) named in this report or his/her relatives individually own one per cent or more securities of the company(ies) covered under this report, at the relevant date as specified in the SEBI (Research Analysts) Regulations, 2014.

The Research Analyst(s) principally responsible for the preparation of this research report and members of their household are prohibited from buying or selling debt or equity securities, including but not limited to any option, right, warrant, future, long or short position issued by company(ies) covered under this report. The Research Analyst(s) principally responsible for the preparation of this research report or their relatives (as defined under SEBI (Research Analysts) Regulations, 2014); (a) do not have any financial interest in the company(ies) covered under this report or (b) did not receive any compensation from the company(ies) covered under this report, or from any third party, in connection with this report or (c) do not have any other material conflict of interest at the time of publication of this report. Research Analyst(s) are not serving as an officer, director or employee of the company(ies) covered under this report.

While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and JM Financial Institutional Securities does not warrant its accuracy or completeness. JM Financial Institutional Securities may not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This report is provided for information only and is not an investment advice and must not alone be taken as the basis for an investment decision.

The investment discussed or views expressed or recommendations/opinions given herein may not be suitable for all investors. The user assumes the entire risk of any use made of this information. The information contained herein may be changed without notice and JM Financial Institutional Securities reserves the right to make modifications and alterations to this statement as they may deem fit from time to time.

This report is neither an offer nor solicitation of an offer to buy and/or sell any securities mentioned herein and/or not an official confirmation of any transaction.

This report is not directed or intended for distribution to, or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject JM Financial Institutional Securities and/or its affiliated company(ies) to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this report may come, are required to inform themselves of and to observe such restrictions.

Persons who receive this report from JM Financial Singapore Pte Ltd may contact Mr. Ruchir Jhunjhunwala (ruchir.jhunjhunwala@jmfli.com) on +65 6422 1888 in respect of any matters arising from, or in connection with, this report.

Additional disclosure only for U.S. persons: JM Financial Institutional Securities has entered into an agreement with JM Financial Securities, Inc. ("JM Financial Securities"), a U.S. registered broker-dealer and member of the Financial Industry Regulatory Authority ("FINRA") in order to conduct certain business in the United States in reliance on the exemption from U.S. broker-dealer registration provided by Rule 15a-6, promulgated under the U.S. Securities Exchange Act of 1934 (the "Exchange Act"), as amended, and as interpreted by the staff of the U.S. Securities and Exchange Commission ("SEC") (together "Rule 15a-6").

This research report is distributed in the United States by JM Financial Securities in compliance with Rule 15a-6, and as a "third party research report" for purposes of FINRA Rule 2241. In compliance with Rule 15a-6(a)(3) this research report is distributed only to "major U.S. institutional investors" as defined in Rule 15a-6 and is not intended for use by any person or entity that is not a major U.S. institutional investor. If you have received a copy of this research report and are not a major U.S. institutional investor, you are instructed not to read, rely on, or reproduce the contents hereof, and to destroy this research or return it to JM Financial Institutional Securities or to JM Financial Securities.

This research report is a product of JM Financial Institutional Securities, which is the employer of the research analyst(s) solely responsible for its content. The research analyst(s) preparing this research report is/are resident outside the United States and are not associated persons or employees of any U.S. registered broker-dealer. Therefore, the analyst(s) are not subject to supervision by a U.S. broker-dealer, or otherwise required to satisfy the regulatory licensing requirements of FINRA and may not be subject to the Rule 2241 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

JM Financial Institutional Securities only accepts orders from major U.S. institutional investors. Pursuant to its agreement with JM Financial Institutional Securities, JM Financial Securities effects the transactions for major U.S. institutional investors. Major U.S. institutional investors may place orders with JM Financial Institutional Securities directly, or through JM Financial Securities, in the securities discussed in this research report.

Additional disclosure only for U.K. persons: Neither JM Financial Institutional Securities nor any of its affiliates is authorised in the United Kingdom (U.K.) by the Financial Conduct Authority. As a result, this report is for distribution only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Financial Promotion Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the matters to which this report relates may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). This report is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this report relates is available only to relevant persons and will be engaged in only with relevant persons.

Additional disclosure only for Canadian persons: This report is not, and under no circumstances is to be construed as, an advertisement or a public offering of the securities described herein in Canada or any province or territory thereof. Under no circumstances is this report to be construed as an offer to sell securities or as a solicitation of an offer to buy securities in any jurisdiction of Canada. Any offer or sale of the securities described herein in Canada will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators and only by a dealer properly registered under applicable securities laws or, alternatively, pursuant to an exemption from the registration requirement in the relevant province or territory of Canada in which such offer or sale is made. This report is not, and under no circumstances is it to be construed as, a prospectus or an offering memorandum. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon these materials, the information contained herein or the merits of the securities described herein and any representation to the contrary is an offence. If you are located in Canada, this report has been made available to you based on your representation that you are an "accredited investor" as such term is defined in National Instrument 45-106 Prospectus Exemptions and a "permitted client" as such term is defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Under no circumstances is the information contained herein to be construed as investment advice in any province or territory of Canada nor should it be construed as being tailored to the needs of the recipient. Canadian recipients are advised that JM Financial Securities, Inc., JM Financial Institutional Securities Limited, their affiliates and authorized agents are not responsible for, nor do they accept, any liability whatsoever for any direct or consequential loss arising from any use of this research report or the information contained herein.